China’s NHSA and MoF Push for DRG/DIP Payment Reforms by 2025
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly released...
Fineline Cube
Sino Biopharmaceutical’s Tulobuterol Patch Gains NMPA Approval
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd...
Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up...
AstraZeneca’s 2024 Financials Beat Expectations with 21% Revenue Growth
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) reported total revenues of USD 54.07 billion in...
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...
GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines
UK-based pharmaceutical giant GSK plc (NYSE: GSK) released its Q4 and full-year 2024 financial results,...
MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) released its Q4 2024 financial report,...
Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth
Amgen (NASDAQ: AMGN) released its Q4 2024 financial results this week, reporting USD 33.42 billion...
Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care
Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...
Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy
Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...
Roche’s Susvimo Approved by FDA for Diabetic Macular Edema
Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US...
FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer
The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...
Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study
Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...
Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...
Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study
China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...
ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...